Impacts of Mycobacterium phlei combined with Linezolid on clinical efficacy and gut microbiota of patients with multidrug-resistant pulmonary tuberculosis
Objective To observe the impacts of Mycobacterium phlei combined with Linezolid on clinical efficacy and gut microbiota of patients with multidrug-resistant pulmonary tuberculosis(MDR-PTB),proviving a reference for the treat-ment.Methods A total of 100 patients who underwent MDR-PTB treatment in our hospital from May 2021 to May 2022 were randomly grouped into Control group(50 cases,conventional treatment+Linezolid)and Observation group(50 cases,conventional treatment+Linezolid+Mycobacterium phlei)randomly.The immune function,laboratory indicators,gut microbiota,clinical efficacy,and adverse reactions were compared between the two groups.Results After treatment,both groups showed an increase in IgM,IgG and CD4+cells,and a decrease in CD8+cells;the observation group showed a more obvious changes in the indicators(all P＜0.05).After treatment,soluble intercellular adhesion molecule(sICAM-1),prostaglandin E2(PGE2),and hypersensitive C-reactive protein(hs-CRP)decreased in both groups,and the observation group showed a more obvious decrease(all P＜0.05).In the observation group,the levels of Ace index,Chao index,Shan-non index and the counts of Escherichia coli,Ruminococcus and Bifidobacterium were higher,while the Simpson index,Enterococcus,Streptococcus and Klebsiella were lower than those in control group,respectively(all P＜0.05).The total clinical efficiency rate in observation group was higher than that in control group(98.00％vs 84.00％,P＜0.05).The incid-ence of adverse reactions in observation group was obviously lower than that in control group(8.00％vs 26.00％,P＜0.05).Conclusion The combination of Mycobacterium phlei and Linezolid can effectively improve the clinical efficacy and reg-ulate gut microbiota in MDR-PTB patients.
万方数据
维普
